Table 2 Summary of enrichment analysis on survival significant modules detected by different algorithms
| Â | Biological processes | Pathways | Cytobands |
|---|---|---|---|
TPSC-w | Cell cycle and mitotic process (G1, G12) | HTLV-I infection and Prostate cancer (G1) | 3p21.3 and 8p12-p11 (G1) |
| Â | Â | P53 signaling, PI3K-AKt signaling and FOXO signaling pathway (G12) | 7q21.3, 1q32 and 17q22-q23 (G12) |
| Â | Â | Â | 17q11.2(G1, G12) |
TPSC-1 | Extracellular matrix and structure organization, blood vessel development, cell adhesion and motility (M6) | Extracellular matrix organization, collagen formation and ensemble of genes encoding ECM-associated proteins (M6) | 11q22.3 and 13q34 (M6) |
| Â | Response to growth hormone (M16) | Pathways related to RHO GTPases (M21, M23) | 17q11.2 and 6q22-q23 (M16) |
| Â | Cell cycle and mitotic process (M21, M23) | Proteoglycans in cancer and circadian clock (M21) | 1p32 (M23) |
| Â | Â | Antifolate resistance (M23) | Â |
WGCNA | Cell cycle and mitotic process (W2) | P53 signaling, oocyte meiosis and PI3K-AKt infection (W2) | 20q11.2 and 12q13.12 (W2) |
| Â | Activation of T cell, lymphocyte and leukocyte (W13) | Cytokine, NF-Kappa B, chemokine and TNF signaling(W13) | 1q31-q32, 1p36 and 1q23 (W13) |
lmQCM | Cell cycle and mitotic process(Q4) | RHO GTPases pathways, P53 pathways, oocyte meiosis and HTLV-I infection (Q4) | 12q13.12, 2p24.2, 15q15.1 and 4q27(Q4) |
| Â | Epithelial cell development and mammary gland development (Q7) | ERBB2- and ERBB4-related signaling (Q7) | 4q31.21 and 1p33(Q7) |